0001209191-21-015517.txt : 20210301
0001209191-21-015517.hdr.sgml : 20210301
20210301210941
ACCESSION NUMBER: 0001209191-21-015517
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210225
FILED AS OF DATE: 20210301
DATE AS OF CHANGE: 20210301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LOEB GARY
CENTRAL INDEX KEY: 0001561733
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30171
FILM NUMBER: 21700886
MAIL ADDRESS:
STREET 1: 5885 HOLLIS ST., SUITE 100
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC
CENTRAL INDEX KEY: 0001001233
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 680359556
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7000 MARINA BLVD
CITY: BRISBANE
STATE: CA
ZIP: 94005
BUSINESS PHONE: 5109706000
MAIL ADDRESS:
STREET 1: 7000 MARINA BLVD
CITY: BRISBANE
STATE: CA
ZIP: 94005
FORMER COMPANY:
FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC
DATE OF NAME CHANGE: 20000208
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-02-25
0
0001001233
SANGAMO THERAPEUTICS, INC
SGMO
0001561733
LOEB GARY
C/O SANGAMO THERAPEUTICS, INC.
7000 MARINA BLVD
BRISBANE
CA
94005
0
1
0
0
EVP, General Counsel & Sec.
Common Stock
2021-02-25
4
F
0
5762
11.19
D
44781
D
Common Stock
2021-02-25
4
A
0
44000
0.00
A
88781
D
Stock Option (Right to Buy)
11.19
2021-02-25
4
A
0
88000
0.00
A
2031-02-24
Common Stock
88000
88000
D
Represents shares underlying the portion of restricted stock unit ("RSU") grant that vested on February 25, 2021 which were surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on February 25, 2021 of $11.19/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended").
Includes: (a) 291 shares of common stock and 252 shares of common stock acquired by the Reporting Person on April 30, 2021 and October 30, 2020, respectively under the Issuer's 2010 Employee Stock Purchase Plan, as amended; and (b) 10,903 shares resulting from the February 25, 2021 vesting of the Reporting Person's February 25, 2020 RSU grant and 33,335 shares subject to such RSU grant that will vest in two remaining annual installments of 16,665 shares and 16,670 shares on February 25, 2022 and 2023 respectively. The vesting of all such RSUs is subject to the Reporting Person's continued service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended.
Represents 44,000 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on February 25, 2021 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended.
One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of Continuous Service, as defined in the 2018 EIP, as amended, by the Reporting Person measured from the February 25, 2021 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through each such vesting date, and subject to acceleration as provided in the 2018 EIP, as amended.
/s/ Matthew Colvin, Attorney-in-Fact for Gary Loeb
2021-03-01